Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals

    Published: May 22, 2023 | Price: $5,000.00 – $10,000.00

    This report, Kalorama's Cell and Gene Deals and Market Analysis, tracks the dealmaking and market opportunity for cell and gene therapy companies.  A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama's latest report finds that the volume of deals between companies and other funding entities involving CGT is up, and companies have continued to receive large amounts of investment despite a decline from 2021 levels of investment. Kalorama's CGT deals...
    Cell Therapy and Gene Therapy Markets, 2021-2031

    Published: February 18, 2022 | Price: $6,000.00 – $12,000.00

    Authoritative Information on Cell and Gene Therapy Markets Cell Therapy And Gene Therapy Markets, 2021-2031 from Kalorama Information presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market) Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions) (Cell Therapy, Gene Therapy, Total Market) Cell...
    Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments

    Published: February 16, 2022 | Price: $5,000.00 – $10,000.00

    Cell and Gene Therapy Funding Reached $70 Billion in 2021. How Can You Keep Up with the Activity in this Industry? A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently.  There are now many approved therapies with proven track records.  As the tools have lowered the barriers to entry for the industry, over a thousand companies have been created or become involved.  Fortunately, Kalorama Information has been tracking every significant development in...